Summary
42.34 -0.52(-1.21%)05/10/2024
Staar Surgical Co. (STAA)
Staar Surgical Co. (STAA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.52 | 1.69 | -5.75 | 57.36 | 33.40 | -31.00 | 69.69 | 201.06 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 46.67 | |
| Open | 46.17 | |
| High | 47.18 | |
| Low | 46.01 | |
| Volume | 586,148 | |
| Change | 0.70 | |
| Change % | 1.52 | |
| Avg Volume (20 Days) | 334,914 | |
| Volume/Avg Volume (20 Days) Ratio | 1.75 | |
| 52 Week Range | 26.66 - 68.27 | |
| Price vs 52 Week High | -31.65% | |
| Price vs 52 Week Low | 75.04% | |
| Range | 1.07 | |
| Gap Up/Down | -0.39 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,106 | |
| EBIDTA | 34,831,000 | |
| PE Ratio | 105.9070 | |
| PEG Ratio | -4.8900 | |
| WallStreet Target Price | 48.28 | |
| Book Value | 7.9050 | |
| Earnings Per Share | 0.4300 | |
| EPS Estimate Current Quarter | 0.1700 | |
| EPS Estimate Next Quarter | 0.1600 | |
| EPS Estimate Current Year | 1.0400 | |
| EPS Estimate Next Year | 0.9100 | |
| Diluted EPS (TTM) | 0.4300 | |
| Revenues | ||
| Profit Marging | 0.0662 | |
| Operating Marging (TTM) | 0.1555 | |
| Return on asset (TTM) | 0.0409 | |
| Return on equity (TTM) | 0.0591 | |
| Revenue TTM | 322,415,008 | |
| Revenue per share TTM | 6.6450 | |
| Quarterly Revenue Growth (YOY) | 0.1910 | |
| Quarterly Earnings Growth (YOY) | 0.2210 | |
| Gross Profit (TTM) | 223,383,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 105.9070 | |
| Forward PE | 175.4386 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 6.3039 | |
| Revenue Enterprise Value | 6.9728 | |
| EBITDA Enterprise Value | 67.6723 | |
| Shares | ||
| Shares Outstanding | 49,131,100 | |
| Shares Float | 37,496,257 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.21 | |
| Insider (%) | 0.51 | |
| Institutions (%) | 106.80 | |
05/07 21:41 EST - Seeking Alpha
STAAR Surgical Company (STAA) Q1 2024 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q1 2024 Results Conference Call May 7, 2024 4:15 PM ET Company Participants Brian Moore - VP, IR Tom Frinzi - President, CEO Patrick Williams - CFO Conference Call Participants Margaret Kaczor - William Blair Tom Stephan - Stifel Patrick Wood - Morgan Stanley Young Li - Jefferies John Young - Canaccord Anthony Petrone - Mizuho George Sellers - Stephens Operator Greetings. Welcome to the STAAR Surgical First Quarter 2024 Earnings Call and Webcast.
STAAR Surgical Company (STAA) Q1 2024 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q1 2024 Results Conference Call May 7, 2024 4:15 PM ET Company Participants Brian Moore - VP, IR Tom Frinzi - President, CEO Patrick Williams - CFO Conference Call Participants Margaret Kaczor - William Blair Tom Stephan - Stifel Patrick Wood - Morgan Stanley Young Li - Jefferies John Young - Canaccord Anthony Petrone - Mizuho George Sellers - Stephens Operator Greetings. Welcome to the STAAR Surgical First Quarter 2024 Earnings Call and Webcast.
05/07 20:30 EST - Zacks Investment Research
Staar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Staar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
04/16 06:25 EST - MarketBeat
Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable Collamer Lenses (ICL) used for the treatment of nearsightedness (myopia), refractive error (astigmatism) and farsightedness (presbyopia).
Star Surgical Shines as U.S. Outlook Improves for 2024
STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable Collamer Lenses (ICL) used for the treatment of nearsightedness (myopia), refractive error (astigmatism) and farsightedness (presbyopia).
04/05 10:16 EST - Zacks Investment Research
Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength?
Staar Surgical (STAA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength?
Staar Surgical (STAA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
04/05 10:13 EST - Invezz
What's going on with STAAR Surgical shares?
STAAR Surgical (NASDAQ: STAA) received an upgrade from William Blair on Friday. The stock has been moved from Market Perform to Outperform status.
What's going on with STAAR Surgical shares?
STAAR Surgical (NASDAQ: STAA) received an upgrade from William Blair on Friday. The stock has been moved from Market Perform to Outperform status.
02/27 15:01 EST - Zacks Investment Research
Staar Surgical (STAA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Staar Surgical (STAA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
02/26 19:40 EST - Seeking Alpha
STAAR Surgical Company (STAA) Q4 2023 Earnings Call Transcript
STAAR Surgical Company (STAA) Q4 2023 Earnings Call Transcript
STAAR Surgical Company (STAA) Q4 2023 Earnings Call Transcript
STAAR Surgical Company (STAA) Q4 2023 Earnings Call Transcript
02/26 18:31 EST - Zacks Investment Research
Staar Surgical (STAA) Beats Q4 Earnings Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.14 per share a year ago.
Staar Surgical (STAA) Beats Q4 Earnings Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.14 per share a year ago.
02/19 07:00 EST - Business Wire
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close. STAAR will host a conference call and webcast on Monday, February 26 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to dis.
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the fourth quarter ending December 29, 2023, on Monday, February 26, 2024, after the market close. STAAR will host a conference call and webcast on Monday, February 26 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to dis.
12/17 12:35 EST - InvestorPlace
7 Stocks with Strong Insider Buying: December 2023
Many investors are familiar with the idea that there are many reasons why insiders sell shares, but there's only one reason they buy. Insider buying indicates a belief that a company's stock is undervalued.
7 Stocks with Strong Insider Buying: December 2023
Many investors are familiar with the idea that there are many reasons why insiders sell shares, but there's only one reason they buy. Insider buying indicates a belief that a company's stock is undervalued.
11/01 22:23 EST - Seeking Alpha
STAAR Surgical Company (STAA) Q3 2023 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Anthony Petrone - Mizuho Xuyang Li - Jefferies John Young - Canaccord George Sellers - Stephens Margaret Kaczor Andrew - William Blair Steve Lichtman - Oppenheimer Operator Good day ladies and gentlemen.
STAAR Surgical Company (STAA) Q3 2023 Earnings Call Transcript
STAAR Surgical Company (NASDAQ:STAA ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Brian Moore - Vice President-Investor Relations & Corporate Development Tom Frinzi - President & Chief Executive Officer Patrick Williams - Chief Financial Officer. Conference Call Participants Anthony Petrone - Mizuho Xuyang Li - Jefferies John Young - Canaccord George Sellers - Stephens Margaret Kaczor Andrew - William Blair Steve Lichtman - Oppenheimer Operator Good day ladies and gentlemen.
10/25 14:53 EST - Market Watch
These healthcare stocks should come to life as boomers live their golden years
Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healthcare.
These healthcare stocks should come to life as boomers live their golden years
Baby boomers: Love ‘em or hate ‘em, the juggernaut generation changes every aspect of life it steamrolls through. Now it's doing the same to healthcare.
10/24 12:28 EST - Seeking Alpha
STAAR Surgical: Not In My Sight Yet
STAAR Surgical Company has developed the EVO ICL Lens to treat nearsightedness, offering clear vision without the hassle of contact lenses or glasses. The EVO ICL Lens has gained market share, with the EVO category capturing over 10% of the global market. STAAR's sales and operating profits have been growing steadily, with a net cash position and a valuation of $2.5 billion. However, sales growth is slowing down.
STAAR Surgical: Not In My Sight Yet
STAAR Surgical Company has developed the EVO ICL Lens to treat nearsightedness, offering clear vision without the hassle of contact lenses or glasses. The EVO ICL Lens has gained market share, with the EVO category capturing over 10% of the global market. STAAR's sales and operating profits have been growing steadily, with a net cash position and a valuation of $2.5 billion. However, sales growth is slowing down.
08/09 02:36 EST - Seeking Alpha
STAAR Surgical: Economic Realities Beginning To Surface, Reiterate Hold
STAAR Surgical Company's Q2 FY'23 earnings missed consensus estimates. The key revenue driver for STAA is its Implantable Collamer Lenses, which saw a 21% YoY increase in unit volumes. Despite potential topline growth, the economic realities and valuation multiples suggest STAA is a hold in my opinion.
STAAR Surgical: Economic Realities Beginning To Surface, Reiterate Hold
STAAR Surgical Company's Q2 FY'23 earnings missed consensus estimates. The key revenue driver for STAA is its Implantable Collamer Lenses, which saw a 21% YoY increase in unit volumes. Despite potential topline growth, the economic realities and valuation multiples suggest STAA is a hold in my opinion.
08/07 07:00 EST - Business Wire
STAAR Surgical to Participate in Upcoming Investor Conferences
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that management will participate in several upcoming investor conferences. STAAR management will participate in the following investor conferences: Canaccord Genuity Annual Growth Conference, Wednesday, August 9. Management Presentation and Q&A at 10:00 a.m. Eastern / 7:00 a.m. Pacific at the following link: https://ws.
STAAR Surgical to Participate in Upcoming Investor Conferences
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that management will participate in several upcoming investor conferences. STAAR management will participate in the following investor conferences: Canaccord Genuity Annual Growth Conference, Wednesday, August 9. Management Presentation and Q&A at 10:00 a.m. Eastern / 7:00 a.m. Pacific at the following link: https://ws.
08/07 05:00 EST - InvestorPlace
3 ‘Strong Buy' Growth Stocks You Should Be Loading Up On Now
Growth stocks are on a tear this year, and while some names will inevitably cool off in the coming weeks, opportunities will always exist. In my opinion, investors should start taking profits from growth stocks trading above their intrinsic value, reinvesting into high-growth companies that trade with a large margin of safety.
3 ‘Strong Buy' Growth Stocks You Should Be Loading Up On Now
Growth stocks are on a tear this year, and while some names will inevitably cool off in the coming weeks, opportunities will always exist. In my opinion, investors should start taking profits from growth stocks trading above their intrinsic value, reinvesting into high-growth companies that trade with a large margin of safety.
08/02 18:43 EST - Zacks Investment Research
Staar Surgical (STAA) Q2 Earnings Beat Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.40 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.42 per share a year ago.
Staar Surgical (STAA) Q2 Earnings Beat Estimates
Staar Surgical (STAA) came out with quarterly earnings of $0.40 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.42 per share a year ago.
07/19 07:00 EST - Business Wire
STAAR Surgical to Report Second Quarter Results on August 2, 2023
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the second quarter ended June 30, 2023 on Wednesday, August 2, 2023 after the market close. STAAR will host a conference call and webcast on Wednesday, August 2 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the confer.
STAAR Surgical to Report Second Quarter Results on August 2, 2023
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses for the eye, today announced that it will release financial results for the second quarter ended June 30, 2023 on Wednesday, August 2, 2023 after the market close. STAAR will host a conference call and webcast on Wednesday, August 2 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and operational progress. To access the confer.
05/26 23:35 EST - Seeking Alpha
I See Opportunity In STAAR Surgical
STAAR Surgical is on the cusp of an acceleration in earnings and growth courtesy of its entrance into the US market. It is profitable, generates positive cash flow, and has zero real debt.
I See Opportunity In STAAR Surgical
STAAR Surgical is on the cusp of an acceleration in earnings and growth courtesy of its entrance into the US market. It is profitable, generates positive cash flow, and has zero real debt.
05/17 10:10 EST - The Motley Fool
2 Stocks With Unstoppable Growth Potential for the Next Decade
These companies get their edge from medical products that are an improvement over existing treatments. Align Technology is building out its manufacturing capacity to expand globally.
2 Stocks With Unstoppable Growth Potential for the Next Decade
These companies get their edge from medical products that are an improvement over existing treatments. Align Technology is building out its manufacturing capacity to expand globally.